Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Jan 21, 2010

Roche Expands Agreement with b3 bio to Include Therapeutic Technologies

  • b3 bio signed an agreement with Roche to source and develop innovative early-stage technologies that could result in potential therapeutic benefits. Roche will have certain rights for further development and/or commercialization of such technologies. As part of this agreement, Roche will increase its equity investment in b3 bio as well as provide development funds.

    b3 bio and Roche started their partnership in July, 2008. The initial arrangement focused on the development of delivery systems for a range of drug candidates and diagnostic cargos.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »